In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Veryan Medical Ltd.

www.veryanmed.com

Latest From Veryan Medical Ltd.

LINC 2018: More Data Demo IN.PACT's Impact, And Other Vasc-Device Findings

The 2018 Leipzig Interventional Course (LINC), Jan. 30-Feb. 2, featured presentations of data from trials of peripheral stents from Biotronik and Veryan, TVA Medical's arteriovenous fistula, and drug-coated balloons from Medtronic, Boston Scientific, and Spectranetics.

Cardiovascular Clinical Trials

Novate: Re-Newing The IVC Filter Market

Serial medtech entrepreneurs Chas Taylor and Paul Gilson founded Novate Medical Ltd. to develop a bioconvertible inferior vena cava filter – it protects patients from pulmonary embolisms during a critical interval, then integrates into the vessel wall. There is no need to retrieve it, a benefit that goes far beyond the economics of avoiding a second procedure.

Medical Device

Medtech Start-Up Financing Strategies: Where’s The Money?

Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.

Medical Device Europe

Drug-Coated Balloons Fuel Multibillion-Dollar Hopes

With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Veryan Holdings Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Veryan Medical Ltd.
  • Senior Management
  • Chas Taylor, CEO
    Colin Caro, Dir., Research
  • Contact Info
  • Veryan Medical Ltd.
    Phone: (44) 403 258 984
    Brighton Rd.
    Units 5-17
    Horsham, RH135BB
    UK
UsernamePublicRestriction

Register